New oral anticoagulants: A multidisciplinary approach;Nuevos anticoagulantes orales: una visión multidisciplinaria

Medicina Clinica

Volumn 133, Issue 13, 2009, Pages 508-512

  Arcelus, Juan Ignacio ^a   Cairols, Marc ^b   Granero, Xavier ^c   Jiménez, David ^d   Vicente Llau, Juan ^e   Monreal, Manuel ^c   Vicente, Vicente ^f  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d UNIVERSITY OF ALCALÁ   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f UNIVERSITY OF MURCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; DABIGATRAN; ENOXAPARIN; RIVAROXABAN;

ANTICOAGULATION; ARTICLE; DRUG BIOAVAILABILITY; DRUG MECHANISM; HUMAN; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; HUMANS; INTERDISCIPLINARY COMMUNICATION;

EID: 70349742421     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2009.03.027     Document Type: Article

References (13)

1. Weitz J.I., and Bates S.M. New anticoagulants. J Thromb Haemost 3 (2005) 1843-1853
2. Sanford M., and Plosker G.L. Dabigatran etexilate. Drugs 68 (2008) 1699-1709
3. Blech S., Ebner T., Ludwig-Schwellinger E., Stangier J., and Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36 (2008) 386-399
4. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 47 (2008) 285-295
5. Roehrig S., Straub A., Pohlmann J., Lampe T., Pernerstorfer J., Schlemmer K.H., et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl) phenyl]-1,3-oxazolidin-5-yl}methyl) thiophene- 2-carboxamide (BAY 59-7939): An oral, direct factor Xa inhibitor. J Med Chem 48 (2005) 5900-5908
6. Kubitza D., Becka M., Wensing G., Voith B., and Zuehisdorf M. Safety, pharmacodynamics and pharmacokinetics of BAY 59-7939-an oral, direct, factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61 (2005) 873-880
7. Pinto D.J., Orwat M.J., Koch S., Rossi K.A., Alexander R.S., Smallwood A., et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 50 (2007) 5339-5356
8. Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., Van Dijk C.N., Frostick S.P., et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement : A randomized, double-blind, non-inferiority trial. Lancet 370 (2007) 949-956
9. Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., Van Dijk C.N., Frostick S.P., et al. Oral dabigatran etexilate versus subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement : The RE-MODEL randomized trial. J Thromb Haemost 5 (2007) 2178-2185
10. Eriksson B.I., Borris L.C., Friedman R.J., Haas S., Huisman M.V., Kakkar A.K., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New Engl J Med 358 (2008) 2765-2775
11. Lassen M.R., Ageno W., Borris L.C., Lieberman J.R., Rosencher N., Bandel T.J., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. New Engl J Med 358 (2008) 2776-2786
12. Llau J.V., De Andrés J., Gomar C., Gómez-Luque A., Hidalgo F., and Torres L.M. Anticlotting drugs and anaesthestic and analgesic techniques: An update of the safety recommendations. Eur J Anaesth 24 (2007) 287-298
13. Rosencher N., Bonnet M.P., and Sessler D.I. New antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: Management strategies. Anaesthesia 62 (2007) 1154